source
- Definium’s LSD therapy cuts anxiety scores in second late-stage trialDefinium Therapeutics reported that its LSD-based drug DT120 reduced anxiety symptoms in a second late-stage study. In the 12-week trial, patients receiving a 100-microgram dose saw an average 9.8…
- Definium Therapeutics clinches third phase-3 win for LSD anxiety drug, eyes FDA filingDefinium Therapeutics reported another successful phase 3 trial of its LSD‑based anxiety treatment, DT120 ODT. The Panorama study enrolled 245 patients and compared a 100 µg dose of DT120 with pla…